Mar 3, 2025 | In the News
BOSTON – March 3, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added several senior members to its clinical and commercial teams. The...
Oct 1, 2024 | In the News
First and Only Software Validated on Ground-Truth Histology, the Gold Standard for Plaque Characterization BOSTON, Oct. 1, 2024 – Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis...
Jul 22, 2024 | In the News
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software BOSTON, July 22, 2024 – Elucid, a pioneering AI medical technology company providing physicians with imaging...
Jul 18, 2024 | In the News
Multi-center, Retrospective Trial to Assess Prognostic Accuracy of Elucid’s Plaque and Plaque-based FFRCT Software in Patients with Clinically Indicated CCTA SCCT2024, WASHINGTON, D.C., and BOSTON, July 18, 2024 – Elucid, a pioneering AI medical technology company...
Jun 27, 2024 | In the News
Modern Space Allows Room for Growth, Collaboration and Wellness BOSTON, June 27, 2024 — Elucid, a pioneering medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular...
